Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Replimune, Inc.

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
Replimune Provides Update Following Type A Meeting with FDA
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
Replimune Announces Type A Meeting Scheduled with FDA
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.